Industry News
Patrys cleared to extend myeloma trial
Patrys (ASX:PAB) has secured ethics approval to add an Australian site to its planned phase I/IIa trial of cancer drug candidate PAB-SM6 for multiple myeloma. [ + ]
Medical investment today like funding mining exploration and building no mines: investor
The disparity between money invested in medical discoveries compared to commercialisation is akin to investing in mining exploration and nothing else, says Dr Jurgen Michaelis, Executive Director of newly launched Verde Capital, a venture capital fund. [ + ]
AusBiotech 2012: The real ‘valley of death’ is dealing with regulators: Alan Robertson
The gap between applying for marketing approval and receiving the go-ahead from regulators is the real ‘valley of death’ facing biotechs, says Alan Robertson, CEO of Pharmaxis. [ + ]
Day of Awards at AusBiotech 2012
Starpharma, Vaxxas, Dr Andrew Baker and Connor O’Meara all received awards at the AusBiotech 2012 conference in Melbourne last night. [ + ]
Physicists sign up for roadside enlightenment
Two giant advertising billboard signs have been given over to exhibit a piece of art based on a vital but little-known physics equation. [ + ]
Astronomer wins 2012 Prime Minister’s Prize for Science
Professor Ken Freeman has received the $300,000 Prime Minister’s Prize for Science for almost 50 years’ work shaping and changing the human view of galaxies and the universe. [ + ]
AusBiotech 2012: Future of health care depends on reforming regulators
Health regulators need a radical overhaul if the “innovation gap” between research and health care is to be bridged in the future, says Dr Richard Barker. [ + ]
Phosphagenics forms horse supplement JV
Phosphagenics (ASX:POH) has formed a joint venture with a subsidiary of Equine Nutrition Australia to market a line of horse supplements using its TPM delivery technology. [ + ]
Octa Phillip loses fight for Bioxyne
Shareholders in Bioxyne (ASX:BXN) resisted a call by investor group Octa Phillip to remove several directors and cease development of HI 164, instead voting to remove Octa's own MD from the board. [ + ]
Starpharma technology gives glyphosate a boost
Starpharma (ASX:SPL) said agrochemicals produced using its dendrimer program were more effective and rain-resistant than the original formulas during laboratory trials. [ + ]
GI Dynamics to start pivotal US trial of EndoBarrier
GI Dynamics (ASX:GID) has got the all-clear from the FDA to commence a 25-site pivotal trial of EndoBarrier in type 2 diabetes in the US. [ + ]
Green chemistry helps promote sustainable manufacturing
Greener manufacturing in the chemical, pharmaceutical and food industries has received a boost following the establishment of the $24.9 million Victorian Centre for Sustainable Chemical Manufacturing (VCSCM). [ + ]
CSIRO leads additive manufacturing charge with new titanium facility
CSIRO has announced the opening of a new titanium additive manufacturing facility that will be used for developing advanced titanium parts for aerospace, medical, automotive and manufacturing applications. [ + ]
Phosphagenics licenses TPM to Indian pharma
India's Agila Specialties has arranged to license Phosphagenics' (ASX:POH) TPM drug delivery platform, and use it to create an injectable antibiotic product. [ + ]
AusBiotech 2012 special feature: Big deals
Be it through major licensing or development deals, domestic and international expansion, mergers and spin-offs or potentially game-changing research, biotechnology companies across Australia have been making waves in recent months. [ + ]
